Zimmer Biomet Holdings (ZBH) was trading at $123.3 as of April 24, 2017. It has a 50-day moving average of $120.3 and a 200-day moving average of $113.8. As of April 24, 2017, Zimmer Biomet Holdings stock was trading ~30% above its 52-week low of $95.6 on November 14, 2016. It was trading ~7.4% below its 52-week high of $133.2 on October 10, 2016. The company’s share price has risen ~6.8% since the release of its 4Q16 earnings on January 31, 2017.
As of January 5, 2017, Zimmer Biomet Holdings’ peer companies Thermo Fisher Scientific (TMO), Stryker (SYK), and Johnson & Johnson (JNJ) generated returns of around 16%, 24.6%, and 8.4%, respectively, over the last 12 months.
Impact of recent earnings results
Due to the company’s higher-than-expected 4Q16 earnings results, stock prices rose ~1.2% on January 31, 2017. The Health Care Select Sector SPDR Fund (XLV) rose ~1.1% on the day.
According to analyst estimates, the company will generate returns of 9% over the next 12 months. ZBH stock has returned ~14.7% over the last one month. The recent price rise has prompted some analysts to upgrade their stock recommendations and target prices. The stock price rise can be attributed to the company’s new product launches, recent dividend announcement, and positive strategic initiatives.
The stock has returned ~19.2% over the past year, while the S&P 500 Index returned ~17.4% during the same period.